Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prograf (tacrolimus) vs extended-release tacrolimus with mycophenolate in de novo kidney transplant recipients
2015-002886-53Phase 3
- Sponsor
- Astellas Pharma
- Start
- Jul 2015
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus and mycophenolate mofetil in kidney allograft rejection and Immune disorder (2 arms), sponsored by Astellas Pharma. Primary endpoint: Patient and graft survival at 6 months.
02
Drugs
tacrolimusmycophenolate mofetil
03
Conditions
kidney allograft rejectionImmune disorder
Beyond the preview
Go deeper on 2015-002886-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002886-53.